Sort
82,697 grants matching “vaccine development”
Component for Institution # 19-01414
$723,833Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2024 · OD
Component for Institution # 19-01414
$723,833Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2023 · OD
Vervet Research Colony as a Biomedical Resource
$723,833Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2020 · OD
Vervet Research Colony as a Biomedical Resource
$723,833Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2024 · OD
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa
$723,817Edus Houston Warren · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Mechanisms of innate modulation of SIV reservoirs and opportunistic disease in the oral cavity
$723,779Roger Keith Reeves · Beth Israel Deaconess Medical Center · R01 · FY2016 · DE
Mechanisms of innate modulation of SIV reservoirs and opportunistic disease in the oral cavity
$723,779Roger Keith Reeves · Beth Israel Deaconess Medical Center · R01 · FY2017 · DE
Uganda International Center for Excellence in Research
$723,766Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Lead Optimization of DHODH Inhibitors for Malaria
$723,733Margaret A. Phillips · Ut Southwestern Medical Center · R01 · FY2022 · AI
The longer-term impact of prenatal exposure to SARS-CoV-2 infection and the COVID-19 vaccine on behavior, cognition, and brain functioning in the child
$723,710Anna-Sophie Rommel · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · HD
Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting
$723,680Albert Icksang Ko · Yale University · R01 · FY2025 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever
$723,640Jinhong Chang · Baruch S. Blumberg Institute · R01 · FY2019 · AI
Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever
$723,640Jinhong Chang · Baruch S. Blumberg Institute · R01 · FY2018 · AI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses
$723,636Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2023 · AI
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
$723,634David Baker · University Of Washington · R01 · FY2021 · AI
Structure and Function of Flaviviruses
$723,607Michael G Rossmann · Purdue University · R01 · FY2010 · AI
Enterovirus interference with rotavirus vaccine replication and immunity
$723,555Megan T Baldridge · Washington University · R01 · FY2024 · AI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An
$723,506Leonidas A Stamatatos · Fred Hutchinson Cancer Research Center · U19 · FY2018 · AI
mRNA-encoded Cas13 as a pan-respiratory antiviral
$723,501Philip J Santangelo · Emory University · R01 · FY2023 · AI
SIV Transmission in Male NHP
$723,453Christopher Miller · University Of California At Davis · R01 · FY2011 · AI
Genome-Wide Association Study of HIV-1 Host Genetics Among Injection Drug Users
$723,408Eric O Johnson · Research Triangle Institute · R01 · FY2010 · DA
Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches
$723,305Timothy W Bickmore · Northeastern University · R01 · FY2022 · MD
Refocusing the Immune Response to the HIV Envelope Glycoprotein
$723,285Phillip Berman · University Of California Santa Cruz · R01 · FY2010 · AI
Identification and analysis of compensatory mutations that support the evolution of antibiotic resistance in Neisseria gonorrhoeae
$723,275Yonatan H Grad · Harvard School Of Public Health · R01 · FY2023 · AI
Proteomics-Driven Reverse Vaccinology for Gonorrhea
$723,264Aleksandra Elzbieta Sikora · Oregon State University · R01 · FY2025 · AI